Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | PDE10A | Q9Y233 | 6/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.40 |
| ▸ | FEN1 | P39748 | 2/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25430881 | 0.87 | PDE10A (0.42) | PDE10AFEN1ELANETRPA1 | |
| SCHEMBL25429893 | 0.85 | HSD17B10 (0.54) | HSD17B10PDE10ATRPV1TRPA1 | |
| SCHEMBL25427626 | 0.84 | HSD17B10 (0.51) | HSD17B10TRPV1TRPA1 | |
| SCHEMBL25429720 | 0.84 | HSD17B10 (0.55) | HSD17B10TRPV1 | |
| SCHEMBL25431622 | 0.80 | HSD17B10 (0.51) | HSD17B10TRPV1 | |
| SCHEMBL25430635 | 0.80 | HSD17B10 (0.51) | HSD17B10TRPV1 | |
| SCHEMBL25430011 | 0.79 | TTBK1 (0.41) | HSD17B10PDE10ATRPV1ELANE | |
| SCHEMBL25430903 | 0.78 | ALOX5AP (0.49) | PDE10AFEN1 | |
| SCHEMBL25429901 | 0.75 | PDE10A (0.45) | PDE10ATRPV1FEN1 | |
| SCHEMBL30544141 | 0.73 | PDE10A (0.45) | PDE10ATRPV1FEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023146511-A1 | COMPOUNDS AND METHODS OF USE THEREOF | VIVACE THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146511-A1 | COMPOUNDS AND METHODS OF USE THEREOF | VIVACE THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |